Put companies on watchlist
MPH Health Care AG
ISIN: DE000A289V03
WKN: A289V0
Curious about what AI knows about MPH Health Care? Just one click more
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

MPH Health Care AG · ISIN: DE000A289V03 · EQS - Analysts (45 News)
Country: Germany · Primary market: Germany · EQS NID: 18535
13 December 2023 09:41AM

Kaufen


Original-Research: MPH Health Care AG - von First Berlin Equity Research GmbH

Einstufung von First Berlin Equity Research GmbH zu MPH Health Care AG

Unternehmen: MPH Health Care AG
ISIN: DE000A289V03

Anlass der Studie: Neunmonatskennzahlen Empfehlung: Kaufen
seit: 13.12.2023
Kursziel: €62
Kursziel auf Sicht von: 12 Monate
Letzte Ratingänderung: -
Analyst: Ellis Acklin

First Berlin Equity Research hat ein Research Update zu MPH Health Care AG (ISIN: DE000A289V03) veröffentlicht. Analyst Ellis Acklin bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel von EUR 62,00.

Zusammenfassung:
Der NAVPS lag zum Neunmonatszeitpunkt bei €50,40 gegenüber €31,90 in 9M/22 (+58%) Die schleppende Performance der deutschen Small Caps setzte sich im dritten Quartal fort und führte zu einer gemischten Kursentwicklung bei den Kernbeteiligungen von MPH. Die Aktie der CR Energy AG (CRE) brach um 22% ein, während die Aktie von M1 Kliniken im Zeitraum Juli bis September um rund 16% zulegte. Das Geschäft des Lifestyle- und Schönheitsspezialisten lief in letzter Zeit sehr gut, und das Unternehmen verzeichnete in den letzten beiden Quartalen operative Rekordmargen. Das CRE-Geschäft ist trotz der Probleme im Wohnungsbausektor weiterhin stabil. Wir führen den jüngsten Kursrückgang der CRE-Aktie größtenteils auf die allgemein schlechte Stimmung für Immobilienaktien zurück. Wir behalten unsere Kaufempfehlung und unser Kursziel von €62 bei.

First Berlin Equity Research has published a research update on MPH Health Care AG (ISIN: DE000A289V03). Analyst Ellis Acklin reiterated his BUY rating and maintained his EUR 62.00 price target.

Abstract:
NAVPS stood at €50.4 at the nine month juncture vs €31.9 at 9M/22 (+58%). The sluggish performance for German small caps continued in Q3 leading to mixed share price developments for MPH's core holdings. CR Energy AG (CRE) shares slumped 22%, while M1 Kliniken stock climbed some 16% during the July-to-September quarter. Business has been strong of late for the lifestyle and beauty specialist, which reported record operating margins the last two quarters. Meanwhile, CRE operations remain resilient despite the troubles for the home building sector. We trace much of the recent tumble in the CRE share price to generally poor sentiment for property stocks. We maintain our Buy rating on MPH with a €62 TP.

Bezüglich der Pflichtangaben gem. §34b WpHG und des Haftungsausschlusses siehe die vollständige Analyse.

Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/28535.pdf

Kontakt für Rückfragen
First Berlin Equity Research GmbH
Herr Gaurav Tiwari
Tel.: +49 (0)30 809 39 686
web: www.firstberlin.com
E-Mail: g.tiwari@firstberlin.com

-------------------übermittelt durch die EQS Group AG.-------------------

Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

Visual performance / price development - MPH Health Care AG
Smart analysis and research tools can be found here.
MIC: XETR

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.